ACTRN12610000400066: A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with Type 2 Diabetes Mellitus |
|
|
| Active, not recruiting | 2 | 140 | | | ChemoCentryx, Inc., ChemoCentryx, Inc. | Type 2 Diabetes Mellitus | | | | |
2017-003022-32: An open, dose escalation study in patients with Primary Focal Segmental Glomerulosclerosis (FSGS - a type of glomerular disease causes scarring in the kidney) and Nephrotic Syndrom (collection of symptoms due to kidney damage) |
|
|
| Not yet recruiting | 2 | 13 | Europe | CCX140-B, Tablet | ChemoCentryx, Inc., ChemoCentryx, Inc. | Primary Focal Segmental Glomerulosclerosis (FSGS), A type of glomerular disease (disease damaging the glomeruli, the filtering units inside the kidney where blood is cleaned) that causes scarring (sclerosis) in kidney., Diseases [C] - Immune System Diseases [C20] | | | | |